Key Findings:  In this study micronized-palmitoylethanolamide-polydatin (m-PEA-Pol) was effective in reducing pain and urinary frequency associated with treatment-resistant cystitis and bladder pain syndromes. It had a less than significant increase in bladder capacity
Type of Study:  Clinical Trial
Study Sample Size:  32
Study Result:  Positive
Study Location(s):  Italy
Year of Pub:  2019
Cannabinoids Studied:  Palmitoylethanolamide (PEA)
Phytocannabinoid Source:  Not Applicable
Receptors Studied:  GPCR 55, TRPV1, PPARs
DOSING DETAILS   
Study Dosing Objective:  Effective Dose
Established Protocol:  Effective dose
Route of Administration:  Oral (Ingestion)
Dosing Regimen:  400 mg m-PEA plus 40 mg polydatin
Adverse Events:  None of the participants reported adverse events